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Pharmaceutical screen identiﬁes novel target
processes for activation of autophagy with
a broad translational potential
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Autophagy is a conserved homeostatic process active in all human cells and affecting a
spectrum of diseases. Here we use a pharmaceutical screen to discover new mechanisms for
activation of autophagy. We identify a subset of pharmaceuticals inducing autophagic ﬂux
with effects in diverse cellular systems modelling speciﬁc stages of several human diseases
such as HIV transmission and hyperphosphorylated tau accumulation in Alzheimer’s disease.
One drug, ﬂubendazole, is a potent inducer of autophagy initiation and ﬂux by affecting
acetylated and dynamic microtubules in a reciprocal way. Disruption of dynamic microtubules
by ﬂubendazole results in mTOR deactivation and dissociation from lysosomes leading to
TFEB (transcription factor EB) nuclear translocation and activation of autophagy. By inducing
microtubule acetylation, ﬂubendazole activates JNK1 leading to Bcl-2 phosphorylation,
causing release of Beclin1 from Bcl-2-Beclin1 complexes for autophagy induction, thus
uncovering a new approach to inducing autophagic ﬂux that may be applicable in disease
treatment.
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T
he autophagy pathway, deﬁned by a set of autophagy
factors1, plays a broad homeostatic role in cleansing
the cellular interior by removing potentially toxic protein
aggregates, defunct or surplus organelles2,3, and invading
microbes as well as exogenous and endogenous agonists of
inﬂammation4. Autophagy furthermore functions in cellular
metabolism and cell death and survival5,6. Genetic and
mechanistic studies have implicated autophagy in human health
and disease, including cancer7, neurodegeneration8, aging-
associated disorders and conditions3,9, and inﬂammatory and
infectious diseases4.
Autophagy has a broad potential for pharmacological inter-
vention in human diseases3,10, but no treatments have been
implemented thus far using autophagy as a target process. Because
of its signiﬁcance in cancer7, autophagy has been employed in
clinical trials3,11, through the use of rapamycin (autophagy
activator through mTOR inhibition) and hydroxychloroquine, a
generalized acidotropic neutralizer of the lysosomal organelles,
and consequently also an inhibitor of autophagy. These
trials have yielded mixed outcomes with additional results
pointing to possible personalized or otherwise tailored
applications11. Another approach has been to pursue design of
membrane-permeant peptides that can activate12 or inhibit13
autophagy by targeting speciﬁc autophagy regulators, (for
example, Beclin 1).
Several screens of small molecule libraries have been conducted
for compounds that modulate autophagy3,14,15. These screens, in
some cases monitoring only the changes in intracellular LC3
puncta as screen readouts, have yielded an overwhelmingly
large number of drugs affecting autophagy10. An increase
in LC3 puncta, while representing a convenient marker of
autophagy16,17, can result either from induction of initiation or
from a block of autophagic maturation since LC3 is consumed in
autolysosomes18. Here, we discriminated against false positives by
a second tier of autophagy maturation assays. Of many
compounds that presented as hits in the initial imaging-based
screen, only very few passed the more rigorous secondary assays
for functional induction of the complete autophagy pathway
including ﬂux. The most consistent inducer in this smaller subset,
ﬂubendazole, showed effects in diverse biological output assays
enabling cells to clear diverse disease-promoting agents through
autophagy. Most importantly, by dissecting ﬂubendazole
mechanism of action in autophagy induction, we uncovered a
novel dual-role of microtubules, which, when affected
simultaneously by this drug, resulted in induction of the
complete autophagy pathway.
Results
Identiﬁcation of autophagy-modulating drugs. We used high-
content imaging of LC3B puncta, a cell biological marker of
autophagy16,17,19, combined with a stringent secondary assay of
LC3B lipidation, also known as LC3-II conversion19. We carried
out screens for autophagy-modulating drugs in HeLa cells
stably expressing mRFP-GFP-LC3B (exempliﬁed in Fig. 1a;
summarized in Supplementary Fig. 1) and processed ranked
data for presumptive hits shown in Supplementary Table 1.
As a measure of autophagy modulation, two parameters were
quantiﬁed based on green ﬂuorescent protein (GFP) ﬂuorescence
in punctate proﬁles: the number of LC3B puncta per cell16 and
the integrated total area of LC3B puncta per cell. The screen was
carried out with dimethylsulphoxide (DMSO) solutions of
compounds from three libraries: the Prestwick Chemical
Library, the Microsource Spectrum 2000 library and the Johns
Hopkins Library. Collectively, these libraries represent the
majority of the FDA-approved drugs and those drugs that have
been in human trials in Europe and Japan, apart from additional
natural products and bioactive molecules. Only those compounds
that in two independently executed complete library screens
increased LC3 puncta by both parameters monitored, that is, LC3
puncta number and total area per cell (Supplementary Table 1),
were considered further. These compounds were next tested for
dose-dependent response (nM to mM range; Supplementary
Fig. 2) and compared with the effects of pp242, a catalytic
inhibitor of mTOR (Supplementary Fig. 2, last panel) in
two independent experiments. Those drugs (a total of 80;
Supplementary Fig. 1 and Supplementary Table 1) that elicited
concentration-dependent autophagy response in both of the two
dose-response series (Supplementary Fig. 2) were considered as
autophagy modulators. Of these, 55 compounds with a wide
range of structures (Supplementary Fig. 2) and known pharmaco-
logical activities (Supplementary Fig. 1 and Supplementary
Table 1), have not been previously reported as autophagy
regulators, whereas the balance of compounds (a total of 25)
have been previously published, as indicated in Supplementary
Table 1).
A subset of the compounds positive in LC3-puncta based
screens and secondary assessments as above were subjected to
analysis for effects on conversion of endogenous LC3 to its
lipidated form LC3-II, as a measure of autophagy activation17,19.
The cells were treated with compounds in the presence of
baﬁlomycin A1 to block autophagic maturation, and compared
with the effects of pp242, as exempliﬁed in Fig. 1b,c. Treatment
with baﬁlomycin A1 prevents autolysosomal degradation of
LC3-II, thus permitting quantiﬁcation of autophagy induction by
measuring LC3-II/actin levels17,19. Only 30% of compounds
passed this test relative to pp242, and reached a P value
(analysis of variance) of o0.05 (Supplementary Table 2). The
majority of these compounds increased LC3-II conversion
in the presence of baﬁlomycin A1, consistent with being
autophagy inducers. Nevertheless, three of the compounds
(emetine, ethoxyquin and GBR12909) showed negative effects
Figure 1 | Screen of autophagy-modulating drugs. (a) Graph, example (384-plate) from screens of Prestwick, Spectrum and Johns Hopkins libraries
(10mM, 4 h) for autophagy-modulating drugs; high-content (HC) image analysis of LC3B puncta in HeLa cells stably expressing mRFP-GFP-LC3B.
Data, total area of LC3B puncta per cell. DMSO, solvent control; pp242, positive control. (b) LC3B Immunoblot (HeLa lysates; Baﬁlomycin A1 and drugs
used as indicated); see Supplementary Fig. 1. (c) Densitometric analysis; mean±s.e.; *Po0.05 (ANOVA), n¼ 3. ANOVA, one way analysis of variance.
(d) Immunoblot (DMSO or 5 mgml 1 ﬂubendazole-treated HeLa cells) with indicated antibodies. (e) Confocal images of HeLa (DMSO or 5mgml 1
Flubendazole, 1 h) with antibody to LC3B. (f) HC analysis of autophagosomes (LC3B puncta area) in HeLa cells; 1 h ﬂudendazole or DMSO treatment.
(g) Immunoblot analysis (LC3B) of HeLa treated with baﬁlomycin A1 and ﬂubendazole (S.E, Short exposure; L.E, Long exposure). (h) Confocal images of
RFP-LAMP1 (HeLa; treated with DMSO or 5 mgml 1 ﬂubendazole for 1 h); immunoﬂuorescence, LC3B antibody. Bottom, colocalization tracing. (i) HC
image analysis (total area of LC3 & LAMP2 colocalizing signals) following 1 h treatment of HeLa (ﬂubendazole or DMSO). Arrows, colocalizing puncta.
(j) HC analysis of autophagosomes (yellow dots) or autophagolysosomes (red dots) in HeLa stably expressing mRFP-GFP-LC3B (ﬂubendazole or DMSO
for 1 h). (k) Autophagy ﬂux (p62 degradation); HeLa (2 h with compounds±baﬁlomycin A1). (l) HC analysis (p62 degradation); HeLa treated with
DMSO or ﬂubendazole for 2 h. Data, mean±s.e.; Statistics, Student’s t-test. *Po 0.05; **Po 0.01. ﬂuben, ﬂubendazole. Scale bars, 10mm.
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on the LC3-II levels in the LC3-II conversion assay in the
presence of baﬁlomycin A1, and thus acted as inhibitors
of autophagy induction. However, since they caused increase in
LC3B puncta they also blocked autophagic maturation, and
should be considered as novel inhibitors of the whole autophagic
pathway. Signiﬁcantly, among the best and most consistent
inducers of autophagy in all assays was ﬂubendazole (Fig. 1,
Supplementary Fig. 2, and Supplementary Tables 1 and 2)
an anti-helminthic drug and a novel inducer of autophagy
identiﬁed here.
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Flubendazole activates autophagy and autophagic ﬂux.
Flubendazole increased total cellular LC3 levels as determined by
immunoblotting (Fig. 1d), immunoﬂuorescence (Fig. 1e) and high-
content microscopy (Fig. 1f). This was not due to a block in the
autophagic ﬂux because ﬂubendazole caused increased LC3-II
conversion in the presence of baﬁlomycin A1 (Fig. 1b,c,g).
Furthermore, ﬂubendazole-induced LC3Bþ autophagic organelles
were positive for the lysosomal markers LAMP1 and LAMP2
(Fig. 1h,i). The colocalization between ﬂubendazole-induced
autophagic organelles and LAMP1 (Fig. 1h) and a separately car-
ried out high-content analysis of colocalization with LAMP2
(Fig. 1i) indicated that ﬂubendazole-induced autophagic ﬂux. This
was further conﬁrmed using the tandem mRFP-GFP-LC3B probe,
which showed an increase both in yellow puncta (RFPþ GFPþ ;
representing early autophagic organelles) and red puncta (RFPþ
GFP-, representing autolysosomes) after ﬂubendazole treatment
(Fig. 1j)18. Moreover, when p62/sequestosome 1 (p62), a marker
for autophagic degradation20, was monitored (Fig. 1k,l), it was
degraded on ﬂubendazole treatment. This effect was abrogated in
the presence of the autophagic maturation inhibitor, baﬁlomycin
A1, as determined by immunoblotting (Fig. 1k). LC3-p62
colocalization increased in ﬂubendazole-treated cells and the total
p62 cellular content was reduced (Fig. 1l). Thus, ﬂubendazole is a
newly identiﬁed potent inducer of autophagy and autophagic ﬂux.
Flubendazole affects microtubules and displaces mTOR. Next,
we examined the mode of action of ﬂubendazole. We observed that
ﬂubendazole can disrupt the regular microtubules (Fig. 2a,
Supplementary Fig. 3a). This was in keeping with ﬂubendazole
being a member of the benzimidazole family of drugs that
affect tubulin polymerization21. However, in variance with the
other common microtubule depolymerizing agents (nocodazole,
vinblastine and vincristine; Supplementary Table 3), ﬂubendazole
strongly increased acetylated lysine-40 (K-40) tubulins (Fig. 2a,b,
Supplementary Fig. 3a,b), a modiﬁcation known to maintain
stability of microtubules even under depolymerization
conditions22,23. Note that acetylated tubulin in ﬂubendazole-
treated cells stained only partially with a-tubulin antibody, most
likely due to the competition for the antibody of depolymerized
a-tubulin released from dynamic microtubules in the
cytosol (Fig. 2a). Two enzymes, ATAT1 (aTAT1/MEC-17)
acetyltransferase and HDAC6 deacetylase, among others,
regulate acetylation levels of a-tubulin24,25. ATAT1 is a major
a-tubulin acetyltransferase whereas HDAC6 is a main microtubule
deacetylase. We tested the effect of ﬂubendazole on ATAT1 and
HDAC6 levels and found that ﬂubendazole increased the total
amount of ATAT1 without affecting HDAC6 levels (Fig. 2c).
Increased ATAT1 enzyme could be an underlying reason for
enhanced acetylated tubulins in ﬂubendazole-treated cells. Indeed,
when we knocked down ATAT1, the acetylated tubulins in
ﬂubendazole-treated cells were strongly reduced (Supplementary
Fig. 3c). Thus, ﬂubendazole has a dual action—it depolymerizes
dynamic microtubules while stabilizing acetylated microtubules.
The Ser/Thr protein kinase mTOR is localized on the
lysosomal organelles and its activity is dependent on both
nutritional status and lysosomal function26,27. Starvation, a
classical inducer of autophagy, displaces mTOR from lysosome
linked to its inactivation26,27. Treatment of HeLa cells
with ﬂubendazole displaced mTOR from lysosomes (Fig. 2d)
and inactivated mTOR as indicated by the inhibition of
phosphorylation of mTOR downstream effectors, S6 kinase and
4EBP-1 (Fig. 2e). This effect of ﬂubendazole on mTOR signalling
could be explained as a result of disruption of dynamic
microtubules. Microtubules are important for lysosome
movement and their disruption can cause lysosomal stress or
abnormal lysosomal function28, which can lead to mTOR
displacement from lysosome membrane and its inactivation as
observed here (Fig. 2d,e). Inactivation of mTOR signalling on
ﬂubendazole treatment of the cells was accompanied by
attenuated Akt phosphorylation (Supplementary Fig. 4a), which
upstream of mTOR contributes to mTOR activation. Localization
of Akt on microtubules maintains its activity, while disruption of
microtubules reduce activating Akt phosphorylation29. Thus, the
disruption of microtubules by ﬂubendazole plays an important
role in inactivating mTOR signalling therefore leading to
autophagy induction.
Flubendazole activates TFEB and lysosome biogenesis. Activity
of TFEB, a key positive regulator of autophagy and lysosome
biogenesis, is regulated by the status of mTOR on lysosomes30–33.
Under fed conditions, on lysosomal membranes, mTOR
phosphorylates TFEB and inhibits its activity, whereas under
starvation conditions or lysosomal stress, inhibition of mTOR
leads to TFEB activation and its nuclear translocation31,32.
Since ﬂubendazole inactivated mTOR signalling, we next tested
whether ﬂubendazole inﬂuenced TFEB by monitoring its nuclear
translocation and found that the percentage of nuclei showing
TFEB positivity was greatly increased in ﬂubendazole-treated cells
(Fig. 3a,b). Flubendazole increased LC3 levels (both LC3-I and
LC3-II; Supplementary Fig. 4b–d). The increase in LC3-I and
LC3-II levels was reduced by knocking down TFEB. Thus, TFEB
is important for ﬂubendazole-induced increase in LC3 levels, in
keeping with it being a regulator of MAP1LC3B expression33.
Flubendazole increased LC3-II/actin (Fig. 1b–e and
Supplementary Fig. 4c) and LC3B puncta/cell (Fig. 1f,g and
Fig. 3c), which are classical measures of autophagy17. As in the
case of LC3-II/actin levels (Supplementary Fig. 4c), the increase in
LC3 puncta in ﬂubendazole-treated cells also depended on TFEB
(Fig. 3c). A double knockdown of TFEB with TFE3 or MITF
(additional members of the MiT/TFE family of regulators34) in
the same cells did not further reduce LC3 puncta elicited by
ﬂubendazole (Fig. 3c), although the altered morphology of LC3
proﬁles associated with TFEB knockdown (consistent with a
recent report34) was corrected by a concomitant knockdown of
MITF but not TFE3 (Fig. 3c, compare three rightmost panels).
Thus, TFEB is important for ﬂubendazole-induced autophagy.
Next, we analysed the effect of ﬂubendazole on lysosome
biogenesis by monitoring the amount of LAMP1, a marker of
lysosomes. The results showed an increase in total amounts of
LAMP1 by immunoﬂuorescence and immunoblotting following
ﬂubendazole treatment (Fig. 3d,e). LAMP2 was also increased in
ﬂubendazole-treated cells, assessed by high-content microscopy
and analysis (Fig. 3f). These data show that ﬂubendazole
treatment increases lysosome abundance in cells. Consistent with
the ﬂubendazole-mediated activation of TFEB, the transcription
of TFEB target genes, LAMP1 and HEXA was modestly increased
at 1 h following ﬂubendazole treatment (Supplementary Fig. 4e).
This effect was abrogated by a TFEB alone (or in combination
with MITF) knockdowns (Supplementary Fig. 4f). However,
TFEB (alone or in combination with other MiT/TEF factors)
knockdowns did not reduce protein levels of LAMP1 induced by
1 h of ﬂubendazole treatment (Supplementary Fig. 4b,g). This
suggests additional levels of expression control besides transcrip-
tion at which ﬂubendazole acted on LAMP1. The existence of
additional levels of control were exempliﬁed by reduced levels of
ﬂubendazole-induced LAMP1 by brefeldin A (Supplementary
Fig. 5a); brefeldin A prevents activation of ARFs within the
biosynthetic pathway affecting transport of lysosomal proteins
through the secretory pathway, which normally might be limited
by the retrograde transport along microtubules from the Golgi to
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9620
4 NATURE COMMUNICATIONS | 6:8620 | DOI: 10.1038/ncomms9620 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
the endoplasmic reticulum (ER)35. However, additional mecha-
nisms outside of de novo mRNA synthesis are likely involved.
Taken together, these data indicate that ﬂubendazole induces
autophagic initiation by inactivating mTOR but also promotes
lysosomal and autolysosomal maturation.
Flubendazole releases Bcl-2 from Beclin 1. Starvation-induced
acetylation (K-40) of microtubules increases the recruitment
of molecular motors kinesin-1 and JIP-1 (JNK-interacting
protein 1) to microtubules leading to c-Jun N-terminal kinase-1
(JNK1) phosphorylation and activation36,37. Activation of JNK1
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has been shown to lead to Bcl-2 phosphorylation causing
release of Beclin 1 from Bcl-2-Beclin 1 complexes, resulting in
autophagy induction38. Since ﬂubendazole increased acetylation
of microtubules (Fig. 2a,b, Supplementary Fig. 3a), we tested
whether ﬂubendazole affected JNK1-Bcl-2 phosphorylation
and Beclin 1 activation. Treatment with ﬂubendazole
enhanced phosphorylation of JNK1 and Bcl-2 (Fig. 4a). In
coimmunoprecipitation assays, ﬂubendazole reduced Bcl-2
levels in Beclin 1 complexes (Fig. 4b) indicating release of
Beclin 1 from its inhibitor Bcl-2 (ref. 38), allowing for Beclin 1
activation and autophagy initiation. Previous work39 has
indicated that ATAT1 acetylase is required for efﬁcient
initiation of autophagy. Consequently, when we knocked down
ATAT1, this prevented efﬁcient JNK and Bcl-2 phosphorylation
in response to ﬂubendazole (Fig. 4c), and inhibited LC3
puncta induction in ﬂubendazole-treated cells revealed by
quantifying GFP-LC3 puncta in the presence of baﬁlomycin A1
(Fig. 4d).
D
M
SO
Fl
ub
en
da
zo
le
Flag-TFEB
20 μm 20 μm 20 μm
20 μm20 μm20 μm
TO-PRO3 Mergea b
0
20
40
60
80
100
120
*
(%
) N
uc
lea
r T
FE
B 
 
DM
SO
Flu
be
nd
az
ole
LAMP-1
DMSO
30  60 120 30  60 120
Flubendazole
e
Actin
Min
D
M
SO
Fl
ub
en
da
zo
le
d
LAMP-1
LAMP-1
Zoom
Zoom
f
D
M
SO
Fl
ub
en
da
zo
le
LAMP2
nuclei
LA
M
P2
 p
un
ct
a 
pe
r c
el
l
DM
SO
Fl
ub
en
da
zo
le
*
1
2
3
4
5
c
DMSO Flubendazole Flubendazole Flubendazole Flubendazole
LC3B LC3B LC3B LC3B LC3B
Control siRNA Control siRNA TFEB siRNA TFEB+TFE3 siRNA TFEB+MITF siRNA
50,000
100,000
150,000
200,000
250,000
300,000
350,000
LC
3 
in
te
ns
ity
 p
er
 c
el
l
(ar
bit
rar
y u
nit
s)
0
Co
ntr
ol s
iRN
A
Co
ntr
ol s
iRN
A
TF
EB
 siR
NA
TF
EB
+T
FE
3 s
iRN
A
TF
EB
+M
ITF
 siR
NA
DMSO
Flubendazole
*
*
100
35
Mr (kDa)
20 μm
20 μm
20 μm
20 μm
20 μm
20 μm
20 μm
Figure 3 | Flubendazole activates TFEB nuclear translocation to induce autophagy. (a) Confocal images of FLAG-TFEB transfected HeLa cells treated
with DMSO or ﬂubendazole (2 h, 5mgml 1) and subjected to nuclear stain (TO-PRO3) and Flag immunostaining (Flag-TFEB). Scale bars, 20mm. (b) Graph
shows percentage of cells with nuclear TFEB±s.d. (n¼ 3;4100 cells from 20 ﬁelds total). *Po0.05 (Student’s t-test). (c) Confocal images of HeLa cells
knocked down for TFEB and other TFE/MiTF family members as indicated were treated with DMSO or ﬂubendazole (1 h, 5 mgml 1) and immunostained for
LC3B. Graph, LC3 intensity per cell±s.d. (B30 cells per condition was analysed using ImageJ, n¼ 3); ANOVA (one way analysis of variance) was used to
test for statistical signiﬁcance: *Po0.05. Scale bars, 20mm. (d) Confocal images of HeLa cells treated with DMSO or ﬂubendazole (1 h, 5 mgml 1) and
immunostained for LAMP1. (e) Immunoblotting analysis of LAMP1 content in DMSO or 5 mgml 1 fubendazole-treated HeLa cells. (f) High-content
analysis of the abundance of lysosomes in HeLa cells treated with ﬂubendazole or DMSO for 1 h. Statistics, mean±s.e.; Student’s t-test. *Po 0.05 (n43).
Scale bars, 10mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9620
6 NATURE COMMUNICATIONS | 6:8620 | DOI: 10.1038/ncomms9620 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
In contrast to other microtubule depolymerizing drugs, which
can increase early autophagosomal organelles but are not
associated with efﬁcient autophagic ﬂux (nocodazole40,41;
taxol41; vinblastine40,41; and vincristine28; Supplementary
Table 3), ﬂubendazole robustly induces autophagic maturation
(Fig. 1g–k). Flubendazole treatment noticeably increases the
acetylated microtubules (Fig. 2a,b, Supplementary Fig. 3a–c),
which are important not only for autophagosome biogenesis but
may also assist fusion of autophagosomes with lysosomes36,37,41.
Accordingly, acetylated microtubules colocalized with auto-
phagosomes even in ﬂubendazole-treated cells (Supplementary
Fig. 5b). Furthermore, ATAT1, which increased on ﬂubendazole
treatment (Fig. 2c), appeared to be required for efﬁcient
maturation/ﬂux as suggested by accumulation of LC3-II
in cells knocked down for ATAT1 on ﬂubendazole treatment
(Fig. 4e). Thus, by affecting the microtubules in a unique manner,
ﬂubendazole promotes both autophagy initiation and maturation,
leading to induction of autophagic ﬂux. Having established
ﬂubendazole’s mode of action in autophagy, we next tested the
autophagy-modulating properties of ﬂubendazole in relevant
cellular systems modelling speciﬁc stages of several human
diseases.
Flubendazole blocks HIV-1 Dendritic cell to T-cell transfer.
Autophagy may counter HIV infection12,42–44. We have
previously reported that autophagy can block transfer of HIV-1
to CD4þ T cells43, a key step during early stages of infection with
HIV45–48. We tested ﬂubendazole for effects on HIV in a cellular
model of infection (DC to T-cell transfer of HIV-1). Immature
dendritic cells (iDCs) were treated with ﬂubendazole and then
infected with HIV-1. The infected iDCs were incubated with
autologous CD4þ T cells, and DC to T-cell transfer of HIV-1 was
measured by staining of CD4þ T cells with anti-Gag antibody.
Flubendazole reduced DC to T-cell transfer of R5-tropic HIV-1 at
multiple time points postinfection (Fig. 5a,b). Flubendazole was
c
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also effective in blocking DC to T-cell transfer of an X4-tropic
HIV-1 (Fig. 5c,d).
To establish that ﬂubendazole decreased DC-CD4þ T-cell-
mediated HIV-1 transfer through autophagy, we studied effects of
LC3 knockdown (Fig. 5e,f) using the previously reported reagents
and approaches43. An efﬁcient downregulation of LC3 expression
of 60–80% with siRNA directed against LC3 was observed when
compared with control siRNA-treated DCs (Fig. 5f). Knockdown
of LC3 in DCs abrogated the inhibitory effects of ﬂubendazole
and Torin 1 (a selective ATP-competitive inhibitor of mTOR
used as a positive control49 on HIV-1 transfer from DCs to T cells
(Fig. 5e,f). Thus, ﬂubendazole limits DC to T-cell transfer of HIV-
1 in an autophagy-dependent manner.
A subset of additional autophagy-inducing drugs from the
screen was tested for efﬁcacy against HIV-1 transfer from DC to
T cells (Supplementary Fig. 6a–c). Flubendazole and rapamycin
(included as a positive control) showed inhibitory effects on DC
to T-cell transfer of HIV-1, whereas other autophagy inducers
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showed a trend but reached no statistical signiﬁcance
(Supplementary Fig. 6a–c). Flubendazole also decreased infection
of DCs with the virus comparable to the effects of AZT
(Fig. 6a,b). When compared with other autophagy-inducing
drugs, ﬂubendazole showed the strongest inhibition of DC
infection with HIV-1, on par with that of rapamycin (Fig. 6c).
Thus, the effect of ﬂubendazole on DC to T-cell transfer can be
explained in part by the effects of ﬂubendazole on DC infection
with HIV-1. However, ﬂubendazole did not have a generalized
effect on HIV-1 yields: although AZT blocked viral expression in
a reporter cell line, ﬂubendazole did not (Supplementary Fig. 6d).
When bromhexine, another agonist of autophagy and autophagy
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ﬂux identiﬁed in our screen (based on multiple assays; Fig. 1c,
Supplementary Tables 1 and 2), was tested in the same assay, it
too inhibited DC infection with HIV-1 (Fig. 6c).
Flubendazole in autophagy of other microbiological targets.
We tested whether ﬂubendazole can promote clearance of other
targets. Crohn’s disease (CD) is a chronic inﬂammatory syn-
drome linked through genome-wide association studies with
autophagy50,51. The human population polymorphisms affecting
autophagy50 inﬂuence its effector outputs including antimicrobial
defence in multiple diseases4,52,53. Adhesive-invasive Escherichia
coli (AIEC) LF82 has been associated with CD (ref. 54). When
HeLa cells were infected with AIEC LF82, ﬂubendazole treatment
promoted delivery of E. coli to the lysosomal compartments, as
revealed by LAMP1 colocalization (Fig. 6d,e; Supplementary
Fig. 7a). Further, ﬂubendazole treatment eliminated intracellular
bacteria in an ATG5-dependent manner (Fig. 6f). This was not
due to uptake differences, since the cells were ﬁrst infected,
treated with gentamycin to kill extracellular bacteria, and only
then treated with ﬂubendazole. Flubendazole had no effect on
viability of AIEC LF82 when added to E. coli culture media
(Supplementary Fig. 7b). Thus, ﬂubendazole can clear diverse
infectious agents through autophagy.
Flubendazole and bromhexine can clear pathological tau. We
tested whether ﬂubendazole can induce autophagy in another cell
type and promote clearance of non-microbiological substrates.
Autophagy has been linked with clearance of tau aggregates in
models of Alzheimer’s disease (AD)55,56. We used neural cells
and a two-pronged induction of tau aggregation (Fig. 7a). First, a
phosphomimetic mutant (T231D/S235D) of human tau was
overexpressed in Neuro2a (N2a) murine neuroblastoma cells.
Second, inﬂammatory signals were provided to accentuate further
tau phosphorylation (occurring on S202 and S396/S404), which
in turn promotes further aggregation57. The inﬂammatory trigger
was exposure of neural cells to conditioned medium (CM) from
lipopolysaccharide (LPS)-activated macrophages (Fig. 7a). CM
induced tau phosphorylation S202 and S396/S404 sites in N2a
cells compared with untreated cells (Fig. 7b,c). Notably, N2a cells
treated with LPS-stimulated macrophage CM showed a higher
level of tau phosphorylation (Fig. 7b,c). Addition of ﬂubendazole
cleared hyperphosphorylated (pS396/S404) tau (Fig. 7b,c). The
reduced tau in ﬂubendazole-treated cells was not due to reduced
cell viability or increased plasma membrane permeability
measured by trypan blue exclusion (Supplementary Fig. 8a) or
LDH release (Supplementary Fig. 8b). Flubendazole-induced
clearance of hyperphosphorylated tau required Beclin 1 (Fig. 7d).
These data indicate that ﬂubendazole, a newly identiﬁed
autophagy agonist, helps ameliorate pathological tau in this
model system.
Bromhexine, another autophagy-inducing drug introduced in
previous sections, was tested in parallel with ﬂubendazole. N2a
cells treated with bromhexine showed marked reduction in
hyperphosphorylated (pS202 and pS396/S404) tau (Fig. 7b,c).
Both ﬂubendazole and bromhexine reduced the total levels of tau
(Fig. 7b,c; detected by Tau5 antibody). The reduction in
phosphorylated tau and total tau levels was statistically signiﬁcant
in ﬂubendazole or bromhexine-treated N2a cells (Fig. 7c).
Memantine, another central nervous-system active pharmaceu-
tical (a glutamate receptor antagonist and a drug used in AD)
identiﬁed by LC3 puncta as an inducer of autophagy
(Supplementary Fig. 2), but not passing all secondary tests
(Supplementary Table 2), did not clear hyperphosphorylated tau
and did not reduce total tau (Fig. 7b,c).
Bromhexine cleared tau phosphorylated on S202 (Fig. 7b,c).
Moreover, bromhexine cleared human tau, detected speciﬁcally
using Tau 12 antibody recognizing only human tau in the
overexpressing N2a cells (Fig. 7e). The reduced tau in
bromhexine-treated cells was not due to increase in cell death
or plasma membrane permeability (Supplementary Fig. 8c,d).
Next, we followed the effect of bromhexine superimposed on a
time course of CM-dependent induction of tau hyperpho-
sphorylation (Supplementary Fig. 8). Bromhexine showed con-
sistent and statistically signiﬁcant increase in phospho-tau
clearance over the time course (Supplementary Fig. 8e–i). To
test whether bromhexine-induced clearance of tau was through
autophagy, we knocked down Beclin 1 in N2a cells, and this
prevented phospho-tau and human tau clearance (Fig. 7f). In
addition to the above mechanistic analysis with Beclin 1
knockdowns, overexpression of TFEB33 resulted in clearance of
phosphorylated and human tau (Fig. 7g), in keeping with recently
published data56. Although TFEB did not reduce total tau
(Supplementary Fig. 8j), its overexpression cleared human
hyperphosphorylated tau in N2a cells (Fig. 7g), thus validating
our model system as responsive to autophagy-based clearance of
tau. In conclusion, induction of autophagy with ﬂubendazole,
bromhexine or TFEB expression can lead to reduced pathological
tau in N2a cells.
Discussion
Our data show that ﬂubendazole, a compound that passed all
stages of our screen for inducers of autophagy among
pharmaceuticals, activates autophagy and autophagy ﬂux by
affecting multiple points of the autophagic pathway. This includes
Beclin 1, mTOR and TFEB, as well as ATAT1 as an effector of
ﬂubendazole action that promotes both induction and maturation
of autophagosomes dependent on the above factors (Fig. 8). Our
ﬁndings suggest that it is the concerted action of these seemingly
disparate effects of ﬂubendazole, with many of them being
anchored on microtubules, which engage the principal regulators
of autophagy and bring about strong activation of autophagy and
autophagic ﬂux (Fig. 8). TFEB is one of the above regulators of
autophagy affected by ﬂubendazole, and may participate in the
action of another drug, bromhexine, as discussed below. The
coordinated activation of multiple autophagy regulatory systems
was found to be the underlying cause for strong activation of
autophagy and autophagic ﬂux observed with ﬂubendazole in
follow-up mechanistic assays and biological outputs with diverse
substrates.
The autophagy pathway1 has a broad disease-treatment
potential that is yet to be realized. Numerous screens of small
molecule libraries have been conducted for compounds that
modulate autophagy3,10,14,15,58–61. These screens have been
carried out in many cases with the aim of repurposing existing
drugs. We have used here the known drugs to uncover new
signalling pathways that can be further exploited in autophagy
drug targeting and discovery. Our screen has identiﬁed
ﬂubendazole as one of the more potent autophagy inducers in
our hands. The study of its mechanism of autophagy induction
uncovered that its potency involved simultaneous induction of
several known systems converging on the autophagy pathway.
This coordinated induction of autophagy and autophagic ﬂux was
based on ﬂubendazole’s unique effects on microtubules that both
promoted disruption of dynamic microtubules and at the same
time stabilized acetylated microtubules. This not only promoted
induction of autophagy but also caused effective maturation of
autophagic organelles, thus activating a complete autophagic
pathway from its initiation to maturation. This property was
associated with clearance of diverse substrates in diverse cell types
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or blocking disease-associated processes in vitro: interruption of a
key process of HIV transmission, the transfer of the virus from
DCs to T lymphocytes, reduction in HIV infection of DCs,
elimination of CD-associated invasive bacteria from infected
epithelial cells, and removal of a pathological form of tau from
inﬂamed neural cells. The effects of microtubule dynamics on
autophagy36,37, a somewhat less studied relationship in the
mainstream studies of autophagy, should receive much more
attention in future autophagy drug development. Furthermore,
regulation of acetyltransferases, such as ATAT1 studied here,
along with deacetylating enzymes deserves further attention given
that very recent studies indicate that deacetylation and acetylation
of the core autophagy proteins Beclin 1 and LC3 signiﬁcantly
modulates autophagy62,63.
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Figure 7 | Flubendazole and bromhexine block inﬂammation-induced tau hyperphosphorylation. (a–c) N2a neuroblastoma cells were transfected with
human tau (H-Tau) carrying T231D/S235D disease-associated phosphomimetic mutations and treated with CM (culture supernatant from RAW 264.7
macrophages activated with LPS) for 24 h in the presence or absence of autophagy agonists. Immunoblots for different forms of tau and phosphorylated
states of tau: pS202 Tau, tau phosphorylated at Ser-202; pS396/404 Tau, tau hyperphosphorylated at Ser-396 and Ser-404 sites; H-Tau, transfected
human tau (detected by Tau12 antibody); T-Tau (total, that is, mouse and human, tau detected by Tau5 antibody). (d) Analysis of phosphorylated tau levels
in N2a cells knockdown for Beclin1 and treated with ﬂubendazole. (e) Treatments as in b; lanes and blots as indicated (including human Tau revelaed with
Tau12 antibody). (f) Analysis of phosphorylated tau levels in N2a cells knockdown for Beclin1 and treated with bromhexine. (g) Analysis of
hyperphosphorylated (pS396/404) tau levels in cells cotransfected with mutant H-Tau (T231D/S235D) and Flag-TFEB in N2a cells. TFEB transfection was
detected using anti-Flag antibody. Data, mean±s.e. (n¼ 3); *Po0.05; **Po0.01; ANOVA Tukey’s multiple comparison post hoc test or unpaired t-test.
ANOVA, analysis of variance.
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In addition to ﬂubendazole, bromhexine was found to induce
effective clearance of an important autophagic substrate, hyper-
phosphorylated tau64,65. This property of bromhexine is likely
related to its effects (or the action of its metabolite ambroxol) on
trafﬁcking and activity of the lysosomal enzymes gluco-
cerebrosidase or glucosylceramidase to the lysosome66. Ambroxol
has recently been linked to TFEB activation67, and thus this is the
likely pathway acting on bromhexine stimulation. The two major
hits in our study affect the lysosomal system and engage TFEB
activation, and thus both already provide autophagy-inducing
drugs that promote TFEB activation and may be candidates for
repurposing in diseases where this is advantageous.
The therapeutic promise of autophagy in a variety of human
diseases3,4,7,8,10,11,15 beckons for quick development of
treatments by repurposing the existing drugs. However, caution
must be taken, and expectations for therapeutic index, that is,
beneﬁts versus drug safety, need to be taken into account when
initiating and interpreting clinical trials aimed at using existing
drug for repurposing. For example, the known low toxicity of
ﬂubendazole in several studies68 (unless combined with a potent
cytotoxic drug21), suggest that it could be considered for further
development. Our data indicate that activation of the
autophagolysosomal system via TFEB- and/or MiT/TFE-
inducing drugs with pharmacologies revealed in our study will
be a productive direction in customizing the next generation of
more tailored autophagy drugs.
Methods
Screening of small molecule libraries. Screening of small molecule libraries for
their autophagic regulatory capacities was conducted by using a Cello-
micsArrayScan to quantitate LC3-GFP/red ﬂuorescent protein (RFP) puncta in
HeLa cells. HeLa cells stably transduced with LC3-GFP/RFP tandem construct
generate ﬂuorescent autophagic puncta, which are either green/yellow (early
autophagosomes) or red (late autophagosomes fused with lysosomes, which
degrades the GFP). By quantitating the number or total area of ﬂuorescent puncta
per cell, detection of alterations in autophagic ﬂux and regulation were observed.
Before any actual screening, preliminary experiments were conducted. One
question was which parameter was most sensitive for detecting changes in
autophagy. We tested total puncta area, number, or intensity per cell for both
GFPþ and RFPþ puncta after treatment with pp242, an mTOR inhibitor and
known inducer of autophagy. GFPþ puncta area was the most distinct readout for
induction of autophagy, although other parameters in both the RFP and GFP
channels also showed changes. Other methods of induction of autophagy were
tested for use as positive controls, including starvation and the mTOR inhibitor
rapamycin. However, pp242 was consistently the stronger inducer of autophagy in
this assay, and was used as a control in subsequent screens.
Using the above system, we performed two separate screens on the Prestwick
Chemical Library, the Microsource Spectrum 2000 library and the Johns Hopkins
library, which contain FDA-approved compounds, bioactive molecules, and natural
products, and represent wide functional and chemical diversity. Cells were plated at
5,000 cells per well of 384-well plates overnight. Compounds were added at a ﬁnal
concentration of10 mM using BioTek robotics, incubated for 4 h at 37 C, ﬁxed with
a total concentration of 0.1% paraformaldehyde (PFA), and placed at 4 C
overnight. Each plate had 32 DMSO-only controls and 32 pp242 controls. GFP
puncta area or number per cell was than assessed as above. A hit was deﬁned as
three s.d. above or below the mean of the negative control wells on a given plate.
After two separate screens, compounds that scored as hits on both screens were
analysed further. Images were manually scanned for autoﬂuorescence, precipitation
or apoptosis, and these false positives were removed from further analysis. Dose
responses for each putative inducer compound were compared with the potent
inducer of autophagy pp242. Two separate dose-response (in nM–mM range)
experiments were performed on hits obtained from the screens.
Follow-up tests used LC3-II conversion in the presence of baﬁlomycin A1
(refs 17,19) with statistical analysis in three or more independent experiments
being the ﬁlter for inclusion in subsequent biological assays.
HIV assays. Human monocytes from buffy coats were obtained in accordance
with institutional guidelines of the ethical committee of the University of Cardiff.
Monocytes were puriﬁed after Ficoll gradient separation with CD14 MicroBeads
(MiltenyiBiotec). Usual purity was495% CD14þ . Human monocyte derived
dendritic cells (MDDCs) were generated by incubation of puriﬁed monocytes in
IMDM supplemented with 10% FCS, 2mM L-glutamine, 100 IUml 1 penicillin,
100 mgml 1 streptomycin, 10mM HEPES, 1% non-essential amino acids, 1mM
sodium pyruvate, 500 IUml 1 granulocyte–macrophage-colony-stimulating factor
and 500 IUml 1 IL-4 (both supplied by Strathman Biotec, Germany). On days 2
and 4, a third of the culture medium was replaced with fresh IMDM medium
supplemented with granulocyte–macrophage-colony-stimulating factor and IL-4.
At day 6 immature DCs were harvested and analysed by ﬂow cytometry. Auto-
logous CD4þ T-lymphocytes were puriﬁed with CD4þ T-cell isolation kit II
(MitenyiBiotec) in accordance with the manufacturer’s instructions. Hut-CCR5 cell
line and autologous CD4þ T-lymphocytes were maintained in supplemented
RPMI1640. 293 T human embryonic kidney cells and HeLa P4-R5 (NIH AIDS
Research & Reference Reagent Program) cells were maintained in supplemented
DMEM.
Virus stocks were produced as previously described69 with 293 T cells
transiently transfected with calcium-phosphate coprecipitated proviral plasmid
pR9 or pR8-Bal, encoding for full-length HIV-1 X4 and HIV-1 R5 strain
provirus respectively. Infectious titres of viral stocks were evaluated by limiting
dilution on HeLa P4-R5 cells. Viral titres were expressed as infectious units (IU)
per ml. Approximately 500 ng of p24 gag on 2.5 105 CD4þHeLa P4-R5
corresponds to a MOI of 1. Physical tires were also evaluated by quantiﬁcation
of an HIV-1 p24gag by ELISA kit (Beckman Coulter, Paris, France). capture and
transfer assays, 5 mM Rapamycin (Merck Chemicals Ltd), 50 mgml 1 Zidovudine
(AZT; GlaxoSmithKline) and 1 mM Torin (R&D Systems) were used.
Autophagosome
Lysosome
mTOR (active)TFEB
Nucleus
Dynamic
microtubules 
Acetylated
tubulin 
Autophagosome
Lysosome
mTOR (inactive)
TFEB
Nucleus
Dynamic
microtubules 
Acetylated
tubulin 
Flubendazole
P
JNK (active)
Bcl2
PBeclin1Beclin1
Bcl2
JNK (inactive)
Autolysosome
Autophagy flux
ATAT1
Figure 8 | Model of ﬂubendazole-induced autophagy and autophagy ﬂux. Schematic on the left: under basal conditions, mTOR residing on lysosomes
keeps TFEB inactive in the cytoplasm. Bcl-2 interacts with and blocks Beclin 1 activity. Both of these processes suppress autophagosome biogenesis.
Schematic on the right: Treatment with ﬂubendazole disrupts dynamic microtubules leading to mTOR displacement from lysosomes and its inactivation;
mTOR inactivation causes nuclear translocation of TFEB. In parallel, ﬂubendazole increases cellular ATAT levels and acetylated microtubules, which (a)
promotes phosphorylation of Bcl-2 by JNK1 to disinhibit Beclin 1 and (b) provides tracks for transport of autophagosomes and lysosomes promoting
autolysosome formation. These ﬂubendazole-initiated processes collectively induce autophagy and promote conversion to autolysosomes thus activating
the entire autophagic pathway from its initiation to its maturation stages.
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Antibodies against DC-SIGN, CD3-PE, CD3-APC and ﬂuorescence-activated
cell sorting antibodies were obtained from BD Transduction Laboratories (Franklin
Lakes, NJ). Anti-LC3B (PM036) used for immunoblotting was from MBL
International (Woburn, MA). Anti-actin was from Sigma (St Louis, MO).
Monoclonal anti-HIVgag (KC57-FITC from Beckman Coulter, Miami,FL) was
used for ﬂow cytometry analysis.
For knockdowns in HIV experiments, siLC3-a (sc-106197), siLC3-b (sc-43390)
and siCtrl were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) was used for
transfection in accordance with the manufacturer’s recommendations. 4 105
iDCs were transfected with 200 nM siRNA in 500 ml of IMDM/0.5% FCS medium
in 12-well plates. A second round of transfection was performed 24 h later. Speciﬁc
gene knockdowns were assessed by immunoblotting followed by densitometry
analysis (Quantity One; Bio-Rad Laboratories, Hercules, CA) comparing with non-
transfected and si Ctrl conditions.
For degradation assay, 105 of iDC were plated in 96-round-well plates in 100 ml
ﬁnal volume of IMDM and pretreated or not with drugs Flubendazole (2 mM),
Fluvoxamine (2 mM), Bromhexine (20 mM), Niclosamide (0.2 mM) or Rapamycin
(5mM) for 3–4 h. Cells were washed and challenged overnight with HIV-R5 strain
R8Bal (250 ng HIV-p24). Cells were harvested after 48 h, ﬁxed in 2% PFA,
permeabilized and stained with anti-HIV-Gag-FITC and anti-DC-SIGN-APC.
Experiments were done in triplicates (N¼ 3).
For virus transfer assay, 105 of iDC were plated in 96-round-well plates in
100ml ﬁnal volume of IMDM and pretreated or not Flubendazole (2 mM),
Fluvoxamine (2 mM), Bromhexine (20 mM), Niclosamide (0.2 mM) or Rapamycin as
a control (10mM) for 3–4 h. Cells were then challenged overnight with HIV-1
(MOI of 1 corresponding to 250 ng HIV-p24 for HIV-R5 (strain AD8) or 250 ng
HIV-p24 for HIV-X4 (strain R9). Cells were washed and cocultured with 1 105
autologous CD4þ T cells for 4 days or days 3 and 6 for assay with Flubendazole
only. Cells were harvested, ﬁxed in 2% PFA, permeabilized and stained with anti-
HIV-Gag-FITC and anti-CD3-PE. Experiment representative of N¼ 3
experiments.
For viral replication assay, 105 of iDC were plated in 96-round-well plates in
100ml ﬁnal volume of IMDM and pretreated or not with drug ﬂubendazole (2 mM)
for 3–4 h. AZT (1:200) was used as a control of viral replication and iDCs were
pretreated for 3–4 h. Cells were washed and challenged overnight with HIV-R5
strain R8Bal (250 ng HIV-p24). Cells were harvested after 4 and 11 days, ﬁxed in
2% PFA, permeabilized and stained with anti-HIV-Gag-FITC and anti-DC-SIGN-
APC. Experiments were done in triplicates (N¼ 3).
For viral detection by ﬂow cytometry, after isolation or differentiation, surface
staining of primary cells (monocytes, MDDCs and autologous CD4þ T cells) were
performed at 4 C for 30min with monoclonal antibodies from BD and directed
against the following molecules: CD1a, CD3, CD4, CD8, CD14, CD16, CD19,
CD25, CD45Ro, CD69, CD83, CCR7, DC-SIGN and HLA-DR. Gag p24 expression
was measured on permeabilized cells with anti-Gagp24 (FITC-coupled) mAb
(KC57, Coulter). Isotope-matched monoclonal antibodies were used as negative
controls. Samples were analysed by ﬂow cytometry with a FacsCanto (Becton
Dickinson) and data processed with FlowJo software.
Microscopy analyses and quantiﬁcation. Cells were visualized using a laser
confocal microscope and images were captured using LSM510 software42. For
quantiﬁcation of nuclear translocation of TFEB and colocalization of LF82 and
LAMP1, images from different ﬁelds were captured and proﬁles analysed42.
Microtubule immunostaining and imaging. For microtubule staining, cells were
ﬁxed in formaldehyde (5min) followed by 10min permeabilization with 0.01%
TritonX-100, 1% BSA in phosphate-buffered saline (PBS) and blocking in 1% BSA
in PBS. Abcam antibody ab6161 was used for immunostaining of a-tubulin.
Acetylated tubulins were stained with anti-acetylated monoclonal antibody from
Sigma (clone 6-11B-1, cat # T7451). Immunostained cells were imaged by confocal
microscopy, with constant parameters for excitation, emission, pinhole and
exposure time when levels of immunostained material were compared.
Tau protein accumulation assays. Mouse neuroblastoma cells (Neuro2a or N2a
cells; ATCC, Manassas, VA) were cultured in in Neurobasal media for up to 10
passages before being expanded and plated at a density of 500,000 cells per well for
all the experiments. The mouse RAW 264.7 macrophage cells (ATCC TIB-71) were
maintained in 10% fetal bovine serum (FBS)/DMEM for up to 10 passages before
being expanded into two ﬂasks.
For treatment of N2a cells with ﬂubendazole, bromhexine, or memantine and
macrophage conditioned media (CM); the media in each ﬂask of RAW cells were
replaced with Neurobasal media containing either vehicle (RPMI) or LPS
(1 ngml 1). RAW cells were activated with LPS for 18 h. Before the conditioned
media experiment, N2a cells were transiently transfected with human tau plasmid
(0.4mg DNA per transfection), pRC/CMV n123c (0N3R tau) containing T231D/
S235D mutation (tauT231D/S235D), which mimic phosphorylation on this disease-
speciﬁc site70 using Effectine reagent per manufacturer’s instructions (Qiagen, Cat#
301425). Tau-transfected N2a cells were pretreated for 30min with vehicle
(DMSO), ﬂubendazole (5 mgml 1), bromhexine (60 mM), memantine (30 mM); or
left untreated. After 30min, human tau-expressing N2a cells were treated with
either vehicle- or LPS-treated RAW CM for 6 h (for ﬂubendazole) or 24 h (for
bromhexine and memantine). The cells were rinsed with PBS three times, lysed and
processed for SDS–polyacrylamide gel electrophoresis and western blotting with
4–12% Bis-Tris protein Gel (Life Technologies). The membranes were probed for;
1) tau with AT8 antibody to detect phosphorylated tau at S202/T205 at 1:5000
(Thermo Scientiﬁc); PHF1 antibody to detect phosphorylated tau at S396/S404
at 1:5000 (a kind gift from Dr Peter Davies); Tau5 antibody (ab80579) to
detect both human and mouse tau at 1:5000; Tau12 antibody (ab74137) to detect
only human tau at 1:5000 for both (Abcam); followed by incubations with
respective secondary antibodies (Jackson Immunoresearch) and developed with
enhanced chemiluminescence (ECL; Pierce).
For the time-course kinetic experiment, the N2a cells and RAW cells were
maintained and set up as above. N2a cells were transiently transfected with human
tau(T231D/S235D) before pre-treatment with Bromhexine for 30min or DMSO.
RAW cells were stimulated with LPS (1 ngml 1). LPS-stimulated RAW CM was
added to the tau-transfected, Bromhexine (60 mM) treated, N2a cells. The cells were
lysed at the following time points: 0, 1, 2, 3, 4, 6 and 8 h post-LPS-CM stimulation.
Cells from each treatment were lysed in triplicate.
For the Beclin 1-silencing experiments, the N2a cells expressing tauT231D/S235D
were nucleofected with siRNA to Beclin 1 and treated with LPS-activated
macrophage CM. After 24 h, cells were lysed to detect phosphorylated tau, total
human tau and Beclin 1.
For cotransfection of tau and TFEB, N2a cells were transiently transfected with
a blank vector, tauT231D/S235Donly, TFEB only (FLAG tag33; a kind gift from
Dr Andrea Ballabio), or with both TFEB and tauT231D/S235D plasmids. After 24 h,
cells were to detect phosphorylated tau, autophagy and total human tau.
Transfection of TFEB was detected by probing membranes with anti-FLAG
antibody (Clone M2, Sigma, F1804; 1:1,000.
Bacterial infection assays. For AIEC LF82 survival assay54, THP-1 cells were
infected with AIEC LF82 of MOI of 1:20 for 1 h. To elminate extracellular E.coli,
THP-1 cells were treated with gentamycin (100 mgml 1) for 1 h followed by
incubation in fresh media containing DMSO or ﬂubendazole (5 mgml 1) for
30min. Cells were lysed and surviving bacteria quantiﬁed by plating and
determining colony-forming units.
Protein interactions analyses and immunoblotting. Protein interactions were
analysed by coimmunoprecipitation assays. Brieﬂy, the cells were lysed using
NP-40 buffer (Invitrogen) containing protease inhibitor cocktail (Roche) and
phenylmethylsulfonyl ﬂuoride (PMSF). Lysates were incubated with antibody for
2 h followed by incubation with protein G Dynabeads (Life technologies) for 2 h.
Beads were washed for four times with 1XPBS and then boiled with SDS–
polyacrylamide gel electrophoresis buffer for analysis of interacting protein by
Immunoblotting.
Antibody and dilutions. Antibodies used in this study: ATAT1 (Abcam, ab58742);
LC3B (Sigma, L7543); HDAC6 (Cell Signaling, #7558); JNK1/p-JNK (Cell
Signaling, #9252, #4668); Bcl-2/p-Bcl2 (Cell Signaling, #2870, #2827); LAMP1
(Abcam, ab24170); S6K, pS6K (Cell Signaling, #9202, #9205); 4E-BP1, p4E-BP1
(Cell Signaling, #9644, #2855). For immunoblotting, primary antibodies were used
in 1:1,000 dilution, and for immunoﬂuorescence imaging as 1:100-1:200 dilution,
unless speciﬁed differently. Secondary antibodies were at 1:1,000 dilution.
Un-cropped blots are shown in Supplementary Figs 9–13.
siRNA knockdowns. SMARTpool siGENOME siRNAs from GE Dharmacon were
used for knockdowns.
Statistical analysis. Signiﬁcant differences between groups were calculated with
analysis of variance or Student’s t-test; P values o0.05 were considered signiﬁcant
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